Effects of systemic fluconazole therapy on in vitro adhesion of Candida albicans to buccal epithelial cells and changes of the cell surface proteins of the epithelial cells.
This paper presented the effects of systemic fluconazole therapy via intravenous (IV) and oral (PO) administrations on the adhesion of Candida albicans (C. albicans) to the buccal epithelial cells (BEC) from five treated patients with three candidosis, one mucormycosis and one sporotrichosis and at the same time, an analysis of the cell surface proteins involving candidal adherent receptor in the BEC of the patients in the course of 7 days were exposed to 3H-leucine radiolabeled C. albicans for in vitro candidal adherent assay, and the BEC from first intake day and the last intake day of the patients were extracted by dithiothreitol (DTT)-iodoacetamide treatment for SDS-PAGE. These results indicate that the systemic fluconazole therapy results in the inhibitory effect of candidal adhesion to BEC of treated patients to prevent them from oral candidosis for a prolonged time, which is based on the absent surface protein (35 KDa) of the BEC.
Wu
S
S
Institute of Dermatology, CAMS & PUMC, Nanjing.
Guo
N
N
Hou
Y
Y
D000328:Adult; D000935:Antifungal Agents / Q000494:pharmacology*; D002176:Candida albicans / Q000187:drug effects*; D002180:Candidiasis, Oral / Q000188:drug therapy / Q000473:pathology*; D004848:Epithelium / Q000473:pathology; D005260:Female; D015725:Fluconazole / Q000494:pharmacology*; D006801:Humans; D008297:Male; D009061:Mouth Mucosa / Q000473:pathology*; D009091:Mucormycosis / Q000188:drug therapy / Q000473:pathology; D013174:Sporotrichosis / Q000188:drug therapy / Q000473:pathology; D000267:Tissue Adhesions
D000935:Antifungal Agents; D015725:Fluconazole